Amina Baloch
Primary Care · Oakbrook Terrace, ILNPI 1336698901
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $30.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$805
- Sunovion Pharmaceuticals Inc.$501
- Teva Pharmaceuticals USA, Inc.$405
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$376
- Urovant Sciences Inc$146
- AbbVie$138
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,544100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 22 | $805 |
| Sunovion Pharmaceuticals Inc. | 22 | $501 |
| Teva Pharmaceuticals USA, Inc. | 13 | $405 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $376 |
| Urovant Sciences Inc | 2 | $146 |
| AbbVie | 3 | $138 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Galderma Laboratories, L.p. | 2 | $122 |
| Sumitomo Pharma America, Inc. | 6 | $109 |
| Amgen | 2 | $102 |
| Johnson & Johnson | 4 | $99 |
| Lundbeck LLC | 4 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $85 |
| Philips North America LLC | 1 | $64 |
| AstraZeneca | 1 | $59 |
| Phathom Pharmaceuticals, Inc. | 2 | $52 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Avanir Pharmaceuticals, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Abbott | 1 | $24 |
| CMP Pharma, Inc. | 1 | $20 |
| Indivior Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Viatris Specialty LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,544 in reported general payments places this provider in the 90th percentile of 150 primary care providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 23 | $103,364 |
| EliquisApixaban | 140 | $39,960 |
| GemtesaVibegron | 192 | $25,864 |
| XareltoRivaroxaban | 89 | $21,800 |
| JanuviaSitagliptin Phosphate | 29 | $10,436 |
| MyrbetriqMirabegron | 57 | $10,207 |
| Divalproex Sodium | 114 | $7,900 |
| InvokanaCanagliflozin | 12 | $7,519 |
| TradjentaLinagliptin | 50 | $7,059 |
| Potassium Chloride | 111 | $6,424 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,916 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,688 |
| Levothyroxine Sodium | 509 | $5,516 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $5,054 |
| Atorvastatin Calcium | 388 | $3,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $405 | $103,36423 claims |
| Johnson & JohnsonXarelto, Invokana | $99 | $29,319101 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $109 | $25,864192 claims |
| AstraZenecaBrilinta | $59 | $1,89116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 150 primary care providers in Illinois.
Other primary care in Oakbrook Terrace
- Nicole LorangElk Grove Village$19K
- Allison LindstromChicago$15K
- Rachel ProkopfOak Park$13K
- Dawn ConwayChicago$11K
- Anne MaynardGlen Ellyn$9K
- Megan McLuckieHoffman Estates$9K
- Megan NiemiecNew Lenox$7K
- Ashley CarterChicago$7K
- Blake WoodsMetropolis$6K
- Jennifer VazquezChicago$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.